Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a uighur population

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 1, 2012, Pages 72-78

  Wang, Lei ^a   Ma, Yi Tong ^a   Xie, Xiang ^a   Yang, Yi Ning ^a   Fu, Zhen Yan ^a   Li, Xiao Mei ^a   Liu, Fen ^b   Huang, Ying ^a   Ma, Xiang ^a   Chen, Bang Dang ^b   Yuan, Shan ^b   Sun, Ming Hui ^b   Peng, Xiao ^b   Wang, Bao Zhu ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Xinjiang Key Laboratory of Cardiovascular Disease Research   (China)

Author keywords

gene polymorphism; matrix metalloproteinase 9; myocardial infarction; smoking

Indexed keywords

GELATINASE B;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CHINA; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CHINA; CORONARY ANGIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 84863158819     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611412365     Document Type: Article

References (48)

1. Tobin MD, Braund PS, Burton PR, et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J. 2004 ; 25 (6). 459-467
2. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007 ; 357 (5). 443-453
3. Ashavaid TF, Shalia KK, Kondkar AA, Todur SP, Nair KG, Nair SR.. Gene polymorphism and coronary risk factors in Indian populations. Clin Chem Lab Med. 2002 ; 40 (10). 975-985
4. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low or high risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003 ; 42 (8). 1429-1437
5. Anderson KM, Wilson PW, Odell PM, Kannel WB.. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 ; 83 (1). 356-362
6. Kannel WB.. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J. 1985 ; 110 (5). 1100-1107
7. Yano K, Reed DM, McGee DL.. Ten-year incidence of coronary heart disease in the honolulu heart program. relationship to biologic and lifestyle characteristics. Am J Epidemiol. 1984 ; 119 (5). 653-666
8. Hlatky MA, Quertermous T, Boothroyd DB, et al. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. Am Heart J. 2007 ; 154 (6). 1-8
9. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U.. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994 ; 330 (15). 1041-1046
10. Kallel A, Sediri Y, Sbai MH, et al. The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population. Clin Biochem. 2010 ; 43 (18). 1461-1463
11. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS.. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis. 2010 ; 21 (6). 330-335
12. Fujimaki T, Kato K, Yokoi K, et al. Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals. Atherosclerosis. 2010 ; 210 (2). 468-473
13. Spinale FG.. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 ; 87 (4). 1285-1342
14. Galis ZS, Khatri JJ.. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002 ; 90 (3). 251-262
15. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: A potential role in acute plaque disruption. Stroke. 2000 ; 31 (1). 40-47
16. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003 ; 107 (12). 1579-1585
17. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008 ; 29 (17). 2116-2124
18. Henney AM, Ye S, Zhang B, et al. Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression. Ann N Y Acad Sci. 2000 ; 902: 27-37
19. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med. 1992 ; 326 (21). 1406-1416
20. Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Wilhelmsen L.. Smoking and myocardial infarction. Lancet. 1975 ; l (7904). 415-420
21. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK.. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern. Med. 2003 ; 138 (11). 891-897
22. Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010 ; 16 (5). 579-583
23. Xie X, Ma YT, Yang YN, et al. Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population. Clin Chem Lab Med. 2010 ; 49 (1). 166-171
24. Alpert JS, Thygesen K, Antman E, Bassand JP.. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 ; 36 (3). 959-969
25. Ruiz-Narvaez EA, Yang Y, Nakanishi Y, Kirchdorfer J, Campos H.. ApoC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res. 2005 ; 46 (12). 2605-2613
26. Guidelines subcommittee. J hypertens. 1999 ; 17 (2). 151-183
27. Diabetes mellitus. WHO Tech Rep Ser. 1985 ; 727: 1-104
28. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S.. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999 ; 105 (5). 418-423
29. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999 ; 99 (14). 1788-1794
30. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G.. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1998 ; 309 (pt 1). 299-306
31. O'Farrell TJ, Pourmotabbed T.. Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. J Biol Chem. 2000 ; 275 (36). 27964-27972
32. Morgan AR, Zhang B, Tapper W, Collins A, Ye S.. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med. 2003 ; 81 (5). 321-326
33. Cho HJ, Chae IH, Park KW, et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet. 2002 ; 47 (2). 88-91
34. Haberbosch W, Gardemann A.. Gelatinase B C(1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest. 2005 ; 65 (6). 513-522
35. Alp E, Menevse S, Tulmac M, et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol. 2009 ; 28 (7). 343-350
36. Zhi H, Wang H, Ren L, et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep. 2010 ; 37 (1). 13-20
37. Fallah S, Seifi M, Ghasemi A, Firoozrai M, Samadikuchaksaraei A.. Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J Clin lab Anal. 2010 ; 24 (5). 305-310
38. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003 ; 107 (12). 1579-1585
39. Kim JS, Park HY, Kwon JH, et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J. 2002 ; 43 (4). 473-481
40. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P.. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002 ; 40 (1). 43-48
41. Ockene IS, Miller NH.. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation. 1997 ; 96 (9). 3243-3247
42. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q.. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993 ; 22 (4). 1159-1167
43. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997 ; 95 (3). 594-599
44. Matetzky S, Tani S, Kangavari S, et al. Smoking increases tissue factor expression in atherosclerotic plaques: Implications for plaque thrombogenicity. Circulation. 2000 ; 102 (6). 602-604
45. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000 ; 150 (2). 245-253
46. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G.. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-a and leaves RANTES and MCP-2 intact. Blood. 2000 ; 96 (8). 2673-2681
47. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995 ; 92 (6). 1565-1569
48. Shah PK.. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis. 2002 ; 44 (5). 357-368